Featured Research

from universities, journals, and other organizations

Importance of standardizing drug screening studies

Date:
December 2, 2013
Source:
Institut de recherches cliniques de Montreal
Summary:
A bioinformatics expert has recently published an article stressing the importance of standardizing drug screening studies. The article supports the need for further development and standardization to improve the reproducibility of drug screening studies, as they are important in identifying new therapeutic agents and their potential combinations with existing drugs.

A bioinformatics expert at the IRCM, Benjamin Haibe-Kains, recently published an article stressing the importance of standardizing drug screening studies in the scientific journal Nature. The study supports the need for further development and standardization to improve the reproducibility of drug screening studies, as they are important in identifying new therapeutic agents and their potential combinations with existing drugs.

Dr. Haibe-Kains's article investigated results from two large-scale pharmacogenomic studies -- the Cancer Genome Project (CGP) and the Cancer Cell Line Encyclopedia (CCLE) -- published last year in Nature. The main goal of these studies was to identify genomic biomarkers that could predict patients' response to anticancer drugs. Because cancer patients often exhibit varied responses to anticancer treatments, and evidence indicates that response is determined in part by patient-specific genome alterations, cancer cell line studies have long been used to test the efficacy of therapeutic agents and explore genomic factors associated with drug response. These two studies screened multiple new and approved drugs on nearly 1,000 panels of cancer cell lines, of which 15 drugs and 471 cell lines were common.

"These studies provided us with a unique opportunity to look at the reproducibility of biomarker discovery in preclinical settings," says Dr. Haibe-Kains, Director of the Bioinformatics and Computational Biology research unit at the IRCM. "Our objective was to examine the uniformities and inconsistencies between results from the two independent studies, and assess the potential of building predictive models of drug response on the basis of those results."

Dr. Haibe-Kains and his research team observed overall good consistency of genomic profiles, which contain information about all the genes in the body and can be used to determine response to a drug. However, drug sensitivity measurements used in the two studies were highly inconsistent.

"We believe the reasons for such differences include the lack of standardization in experimental assays and data analysis methods," adds Dr. Haibe-Kains. "For example, the studies tested different drug concentrations and used different statistical models to analyze their data. In addition, due to discrepancies in drug sensitivity data, some potential biomarkers were inconsistent between the two studies."

"These pharmacogenomic studies are generally the first step in a larger experimental pipeline where candidate drugs and biomarkers are further validated in animal studies and human clinical trials," explains Dr. Haibe-Kains. "Our findings support the need for standardization of drug-response measurements or the development of new, robust drug sensitivity assays in order to identify reliable genomic predictors of drug response or effectively identify a drug's mechanism of action."

"It is important to note that our study and the resulting observations could not have been possible if the data had not been well documented and made accessible to the scientific community," concludes Dr. Haibe-Kains. "This represents a big success for open data science and reproducible research, and we would like to thank the investigators from the CGP and CCLE studies who made their invaluable data available to researchers everywhere. Without this data, we would not have been able to discover the discrepancies. We now need to work together to improve the reproducibility of large-scale screening studies so that we can identify new therapeutic agents and their potential combinations with existing drugs."


Story Source:

The above story is based on materials provided by Institut de recherches cliniques de Montreal. Note: Materials may be edited for content and length.


Journal Reference:

  1. Benjamin Haibe-Kains, Nehme El-Hachem, Nicolai Juul Birkbak, Andrew C. Jin, Andrew H. Beck, Hugo J. W. L. Aerts, John Quackenbush. Inconsistency in large pharmacogenomic studies. Nature, 2013; DOI: 10.1038/nature12831

Cite This Page:

Institut de recherches cliniques de Montreal. "Importance of standardizing drug screening studies." ScienceDaily. ScienceDaily, 2 December 2013. <www.sciencedaily.com/releases/2013/12/131202121538.htm>.
Institut de recherches cliniques de Montreal. (2013, December 2). Importance of standardizing drug screening studies. ScienceDaily. Retrieved July 25, 2014 from www.sciencedaily.com/releases/2013/12/131202121538.htm
Institut de recherches cliniques de Montreal. "Importance of standardizing drug screening studies." ScienceDaily. www.sciencedaily.com/releases/2013/12/131202121538.htm (accessed July 25, 2014).

Share This




More Health & Medicine News

Friday, July 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Beatings and Addiction: Pakistan Drug 'clinic' Tortures Patients

Beatings and Addiction: Pakistan Drug 'clinic' Tortures Patients

AFP (July 24, 2014) A so-called drugs rehab 'clinic' is closed down in Pakistan after police find scores of ‘patients’ chained up alleging serial abuse. Duration 03:05 Video provided by AFP
Powered by NewsLook.com
Too Few Teens Receiving HPV Vaccination, CDC Says

Too Few Teens Receiving HPV Vaccination, CDC Says

Newsy (July 24, 2014) The Centers for Disease Control and Prevention is blaming doctors for the low number of children being vaccinated for HPV. Video provided by Newsy
Powered by NewsLook.com
New Painkiller Designed To Discourage Abuse: Will It Work?

New Painkiller Designed To Discourage Abuse: Will It Work?

Newsy (July 24, 2014) The FDA approved Targiniq ER on Wednesday, a painkiller designed to keep users from abusing it. Like any new medication, however, it has doubters. Video provided by Newsy
Powered by NewsLook.com
Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Newsy (July 24, 2014) Sheik Umar Khan has treated many of the people infected in the Ebola outbreak, and now he's become one of them. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins